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ABSTRACT 
Numerous studies demonstrate the significant role of central β-endorphin and its receptor, the μ-
opioid receptor (MOR), in sodium intake regulation. The present study aimed to investigate 
the possible relationship between chronic high-NaCl intake and brain endogenous MOR 
functioning. We examined whether short-term (4 days) obligatory salt intake (2% NaCl 
solution) in rats may induce changes in MOR mRNA expression, G-protein activity and 
MOR binding capacity in brain regions involved in salt intake regulation. Plasma osmolality 
and electrolyte concentrations after sodium overload and the initial and final body weight of 
the animals were also examined. After 4 days of obligatory hypertonic sodium chloride 
intake, there was clearly no difference in MOR mRNA expression and G-protein activity in 
the median preoptic nucleus (MnPO). In the brainstem, MOR binding capacity also remained 
unaltered, but the maximal efficacy of MOR G-protein significantly increased. Finally, no 
significant alterations were observed in plasma osmolality and electrolyte concentrations. 
Interestingly, animals which received sodium gained significantly less weight than control 
animals. In conclusion, we found no significant alterations in the MnPO and brainstem in the 
number of available cell surface MORs or de novo syntheses of MOR after hypertonic 
sodium intake. The increased MOR G-protein activity following acute sodium 
overconsumption may participate in the maintenance of normal blood pressure levels and/or 
in enhancing sodium taste aversion and sodium overload-induced anorexia. 
 
Keywords: µ-opioid receptor signaling, ß-endorphin, sodium ingestion, brainstem, G-protein 
activation.
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ABBREVIATIONS 
Ct: threshold cycle 
ΔCt/ΔΔCt: delta threshold cycle/ double delta threshold cycle 
DAMGO: [D-Ala2,N-MePhe4,Gly5-ol]-enkephalin, selective MOR agonist 
E: efficiency 
EGTA: ethyleneglycol-tetraacetate 
GDP: guanosine 5’-diphosphate 
GTP: guanosine 5’-triphosphate 
GTPγS: Guanosine-5’-O-[γ-thio] triphosphate 
MOR: µ-opioid receptor 
MnPO: median preoptic nucleus 
NTS: nucleus of the solitary tract 
PCR: Polymerase chain reaction 
RT-PCR: real time - polymerase chain reaction 
S.E.M.: standard error of means 
Tris-HCl: tris-(hydroxymethyl)-aminomethane hydrochloride 
 
1 INTRODUCTION 
Several lines of evidence suggest that central endogenous opioid peptides and receptors are 
involved in the regulation of salt ingestion. β-endorphin is one which plays a key role in the 
modulation of salt hedonic palatability and sodium appetite, as well as in dietary-sodium-
overload induced sympathetic and pressor responses(1,2,3,4,5). Previous results from our 
laboratory indicated that β-endorphin knockout mice and heterozygous mutant mice consume 
approximately 50% less 2% NaCl solution than wild-type mice after sodium depletion, 
suggesting that β-endorphin facilitates induced sodium appetite (3). On the other hand, our 
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results also showed that endogenous β-endorphin is implicated in the compensatory response 
to body sodium overload(6,7). This was demonstrated by β-endorphin knockout mice 
displaying increased systolic blood pressure, urinary epinephrine excretion and median 
preoptic nucleus (MnPO) neural activity (as shown by Fos-immunoreactivity), when 
submitted to a high-sodium diet (4% NaCl) for two weeks, while no effect was registered in 
wild-type and heterozygous mice. Additionally, Caeiro and Vivas (2008)(7) showed that β-
endorphin-MnPO administration produces a decrease in blood pressure and heart rate in 
normotensive animals and inhibits the pressor response evoked by an acute increase in 
plasma osmolality.  
Numerous studies demonstrate the significant role of the μ-opioid receptor (MOR) in sodium 
intake regulation. The MOR, together with two other classical types of opioid receptors, κand 
δ, belong to the G-protein coupled receptor (GPCR) superfamily. They predominantly couple 
to Gαi/o type inhibitory G-proteins(8), which leads to the inhibition of adenylyl cyclase 
activity(9), decreases calcium ion entry(10) and increases potassium ion efflux(11). It has been 
demonstrated that central injection of the selective MOR agonist, [d-Ala2,N-MePhe4,Gly5-
ol]-enkephalin (DAMGO), significantly increased the intake of saline solution (at both 0.6% 
and 1.7% NaCl) in non-deprived rats (12). Moreover, systemic injection of morphine increased 
the preference of mice and rats for normally aversive hypertonic NaCl solutions (1.5–30% 
NaCl)(13,14). Increased MOR signaling along the nucleus accumbens, ventral pallidum and 
central amygdala nucleus (CeA) has been mainly associated with the hedonic palatability of 
NaCl when it is tasted(5,15,16,17). MOR activity along the brainstem, within the lateral 
parabrachial nucleus (LPBN) and the nucleus of the solitary tract (NTS), mainly modulates 
motivated sodium/food intake and blood pressure (18,19,20,21).  
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However, experiments such as these fail to determine the mechanisms by which 
endogenous MOR signaling is acting to modulate sodium appetite and blood pressure 
regulation. The present study aimed to investigate the effect of increased salt intake (2% 
NaCl solution) in rats during a short period of time (4 days) on MOR mRNA expression 
along the MnPO and the NTS. We also explored brainstem and MnPO MOR G-protein 
activity (efficacy and potency) and brainstem MOR binding capacity, to see whether sodium 
overload induced any changes in the signaling and binding properties of the MOR in these 
brain regions. Finally, we also examined the changes in plasma concentrations of Na+, K+, 
and Cl- and body weight of the animals after the sodium overload. 
 
MATERIALS AND METHODS 
1.1 Chemicals 
Tris-HCl, EGTA, NaCl, MgCl2 x 6H2O, GDP and the GTP analog GTPγS were 
purchased from Sigma-Aldrich (Budapest, Hungary). The highly selective MOR agonist 
enkephalin analog, Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO), was obtained from Bachem 
Holding AG (Bubendorf, Switzerland). The non-selective opioid receptor antagonist, 
naloxone, was kindly provided by Endo Laboratories of DuPont de Nemours (Wilmington, 
DE, USA). Ligands were dissolved in water and were stored in 1 mM stock solution at -20˚C. 
The radiolabeled GTP analog, [35S]GTPγS (specific activity: 1250 Ci/mmol), was purchased 
from PerkinElmer (Budapest, Hungary). [3H]DAMGO (specific activity: 38.8Ci/ mmol) was 
radiolabeled in the Isotope Laboratory of BRC (Szeged, Hungary) and was previously 
characterized (22). The Ultima GoldTM MV aqueous scintillation cocktail was purchased from 
PerkinElmer (Budapest, Hungary). 
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1.2 Animals 
As a result of collaboration, we used two rat strains provided by each local research 
institute. Male, Wistar-derived rats (350-400 g) from the colony of the Instituto de 
Investigación Médica Mercedes y Martin Ferreyra (INIMEC-CONICET, Universidad 
Nacional de Córdoba, Córdoba Argentina) were used for the relative MOR mRNA 
expression and plasma osmolality and electrolyte analysis. The MOR binding experiments 
were carried out in male Sprague-Dawley rats (200-300 g) obtained from the animal house of 
the Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of 
Szeged (Szeged, Hungary). 
Animals were kept in a temperature-controlled environment, with a 12-h light/dark 
cycle, with food and water ad-libitum until the initiation of the experiments. Each animal was 
used in only one experimental condition. All the experimental protocols in Wistar rats were 
approved and carried out in accordance with the guidelines of the Ferreyra Institute Ethical 
Committee for the use and care of laboratory animals, and the guidelines of the International 
Public Health Service Guide for the Care and Use of Laboratory Animals. Housing and 
experiments performed in Sprague-Dawley rats were in accordance with the European 
Communities Council Directives (2010/63/EU) and the Hungarian Act for the Protection of 
Animals in Research (XXVIII.tv. 32.§, registration number: IV./141/2013.). All efforts were 
made to minimize animal suffering and to reduce the number of animals used. 
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1.3 Experimental design 
As indicated in Figure 1, the experimental group had access only to 2% NaCl solution 
(2% NaCl), whereas the control group (CON) had ad-libitum access to deionized water 
during the 4-day protocol period, after which the animals were used for the appropriate 
experimental setup. Both experimental and control groups had normal access to commercial 
diet. Plasma was collected from both groups (CON and 2% NaCl) at the end of the treatment 
to measure plasma osmolality and electrolyte concentrations. Body weight was measured in 
both groups at the beginning and at the end of the protocol. 
 
 Figure 1. Schematic diagram showing experimental design and protocols. 
1.4 Relative mRNA expression of MOR (Oprm1)  
1.4.1 Brain microdissection, tissue collection, RNA extraction and calibration of primers 
After 4 days of control or sodium overload conditions, the animals were decapitated 
and brains immediately excised and stored at -80°C for mRNA determination. Coronal 
sections of 540 μm in the MnPO and of 780 μm in the nucleus of the solitary tract (NTS) 
were obtained from the frozen brains in a microtome with a stainless-steel punch needle. The 
Day 1 Day 5
Body weight was measured at the 
beginning and at the end of the protocol.
Control group
(CON)
ad libitum access to
deionized water
and commercial diet
Experimental group
(2%NaCl)
access only to 
2% NaCl solution and
commercial diet
Male adult rats
(Wistar/Sprague-Dawley)
4 days of control/sodium overload conditions
Euthanasia -brain removal 
(Relative mRNA expression/
Receptor binding assays )
Plasma collection
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brain nuclei were identified and delimited according to the rat brain atlas(23). The mRNA was 
isolated from micro punches of specific brain areas, using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) as directed by the manufacturer with some modifications: RNA 
precipitation with isopropanol was performed overnight at -20ºC. The RNA was treated with 
DNase (Fermentas) and quantified using a NanoDrop 2000 UV-Vis Spectrophotometer, and 
then reverse-transcribed into cDNA (enzyme RTM-MLV – Promega).  
Brain Oprm1gene expression was determined using Syber Green Real-Time PCR 
Master Mixes (Applied Biosystems™) in the Step One Real-Time equipment (Applied 
Biosystems). PCR amplification efficiency was established by means of 5-point 1:10 
calibration curves. The selected dilution for the samples was 1:10 from the initial RT PCR 
concentration. The Ct values of the samples fell into the linear dynamic range of the 
calibration curve. All primer-pairs were verified to be 90–110% efficient by means of the 
calibration curve, with efficiencies E = 2 ± 0.1 (E = 10[−1/slope]), and amplified a single product 
determined by melting curve analysis. Primer sequences can be found in Table 1. 
Table 1. Primer pairs for Oprm1 and Gapdh mRNAs.  
 Oprm1 Gapdh 
GenBank access number NM_001304737.1 NM_017008.4 
Primer forward 5´- 3´ CTGTCTGCCACCCAGTCAAA TGTGAACGGATTTGGCCGTA
Primer reverse 5´- 3´ TGCAATCTATGGACCCCTGC ATGAAGGGGTCGTTGATGGC 
Product size (bp) 150 93 
Annealing temp. (◦C) 60°C 59°C 
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1.4.2 Calculations of Relative Gene Expression 
The relative quantification was determined by the ΔΔCt method with StepOne 
Software v2.2, where the fold change of mRNA content in the unknown sample relative to 
control group was determined by calculating a ratio = (Etarget)ΔCt(target)/(EGapdh)ΔCt(Gapdh), where 
E is the efficiency of the primer set and ΔCt = Ct(control) − Ct(experimental). For each sample, the 
Ct was determined and normalized to the average of the housekeeping gene, Gapdh. Relative 
quantifications of the target gene (Oprm1) were normalized to each control group. Data are 
presented as mRNA expression relative to the control calibrator group. The 2−ΔCT method was 
used to determine the expression of Gapdh between treatments (CON Vs. NaCl 2%). The 
relative amounts of Gapdh were calculated using the 2−ΔCT equation, where ΔCT = CT treated 
– CT control (24). 
1.5 Receptor binding assays 
1.5.1 Preparation of brain samples for binding assays 
After the final day of treatment, 12 rats for experimental and control conditions were 
decapitated and their brains were quickly removed. The brainstems were prepared for 
membrane preparation according to Benyhe et al.(25) and partly used for saturation binding 
experiments and partly further prepared for the [35S]GTPγS binding protocols, according to 
Zádor et al.(26). The brainstem and median preoptic nucleus (MnPO) were separated 
according to the Paxinos and Watson rat brain atlas(23) and were homogenized and suspended 
in Tris-HCl, EGTA, MgCl2 buffer for [35S]GTPγS binding assays. 
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1.5.2 Functional [35S]GTPγS binding experiments 
The functional [35S]GTPγS binding experiments were performed as previously 
described(27,28), with modifications. Briefly, the membrane fractions of brainstem and MnPO 
homogenates were incubated at 30˚C for 60 min in Tris-EGTA buffer (pH 7.4) composed of 
50 mMTris-HCl, 1 mM EGTA, 3 mM MgCl2, 100 Mm NaCl, containing 20 MBq/0.05 cm3 
[35S]GTPγS (0.05 nM) and increasing concentrations (10-10 – 10-5 M) of DAMGO. The 
experiments were performed in the presence of excess GDP (30 µM) in a final volume of 1 
ml. Total binding was measured in the absence of test compounds, determining non-specific 
binding in the presence of 10 µM unlabeled GTPγS. The difference represents basal activity. 
The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell Harvester) 
and washed three times with 5 ml ice-cold 50 mM Tris-HCl (pH 7.4) buffer through 
Whatman GF/B glass fibers. The radioactivity of the dried filters was detected in an 
UltimaGoldTM MV aqueous scintillation cocktail with a Packard Tricarb2300TR liquid 
scintillation counter. [35S]GTPγS binding experiments were performed in triplicate and 
repeated at least three times. 
1.5.3 Saturation binding experiments 
Aliquots of frozen rat brainstem membrane homogenates were centrifuged (18 000 
rpm, 20 min, 4˚C) to remove sucrose and the pellets were suspended in 50 mM Tris-HCl 
buffer (pH 7.4). Membranes were incubated in the presence of [3H]DAMGO in increasing 
concentrations (1.06 nM – 24.32nM) for 35˚C for 45 min. The non-specific and the total 
binding were determined in the presence and absence of 10 µM unlabeled naloxone, 
respectively. The reaction was terminated by rapid filtration under vacuum (Brandel M24R 
Cell Harvester) and washed three times with 5 ml ice-cold 50 mM Tris-HCl (pH 7.4) buffer 
through Whatman GF/C glass fibers. The radioactivity of the dried filters was detected in an 
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UltimaGoldTM MV aqueous scintillation cocktail with a Packard Tricarb 2300TR liquid 
scintillation counter. The saturation binding assays were performed in duplicate and repeated 
at least three times. 
1.6 Plasma osmolality and electrolyte analysis 
For the assay of plasma osmolality and electrolyte concentrations, we used groups of 
animals different from those used in the relative mRNA expression and receptor binding 
studies. The animals from both groups (CON and 2% NaCl) were decapitated and bled at the 
end of the four days treatment. Trunk blood was collected in chilled tubes containing EDTA 
(final concentration 2 mg/ml blood) for centrifugation at 3000 rpm for 10 min at 4°C. Plasma 
electrolyte concentrations were measured with a Beckman Lablyte system (model 810, 
Beckman Instruments), plasma osmolality was determined from duplicate 8-μl plasma 
samples using vapor pressure osmometry (VAPRO 5520). 
1.7 Data analysis 
1.7.1 Relative mRNA expression of MOR (Oprm1), plasma osmolality, weight and 
electrolyte concentration data 
The relative mRNA expression of MOR (Oprm1), plasma osmolality, weight and 
electrolyte concentration data were subjected to a t-test, and the loci of significant effects 
were further analyzed using the one-way ANOVA Tukey’s test (type I error probability was 
set at 0.05). All experimental data were presented as means ± S.E.M. 
1.7.2 Receptor binding data 
The specific binding of the radiolabeled compounds ([35S]GTPγS, [3H]DAMGO) was 
calculated by subtracting the non-specific binding values from total binding values, and was 
given in percentage. Data was normalized to total specific binding, which was set at 100%, 
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which, in the case of [35S]GTPγS binding assays, also represents the level of G-protein basal 
activity. Experimental data were presented as means ± S.E.M in function of the applied 
ligand concentration range, which, in the case of [35S]GTPγS binding assays, was indicated in 
logarithm form. Points were fitted with the professional curve fitting program, GraphPad 
Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA), using non-linear regression. In 
the [35S]GTPγS binding assays, the ‘Sigmoid dose-response’ fitting was used to establish the 
maximal stimulation or efficacy (Emax) of the G-protein coupled receptors and the ligand 
potency (EC50). Stimulation was given as a percentage of the specific [35S]GTPγS binding 
observed over basal activity, which was set at 100%. In saturation binding assays, the ‘One 
site - specific binding’ fitting equation was applied to establish the concentration of the 
radioligand that produced 50% of the maximal binding capacity or, in other words, the 
dissociation constant (Kd) and the maximum binding capacity of the receptor (Bmax). The 
amount of receptors which specifically bound [3H]DAMGO was presented in fmol/mg, 
calculated by the total protein content and the amount of radioligand in the appropriate 
concentration point, and by the specific activity of the radioligand. Unpaired t-test with two-
tailed P-value was performed to determine the significance level, using Graph Pad Prism 5.0. 
Significance was accepted at the P < 0.05 level. 
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2 RESULTS 
2.1 Relative gene expression of the MOR (Oprm1) 
After treatments (CON and 2% NaCl), no significant differences were observed in 
relative gene expression of the μ-opioid receptor (Oprm1) in any of the brain nuclei analyzed 
(Fig. 2). 
 
 
 
 
Figure 2. Relative mRNA expression of opioid receptor Mu1 (Opr1), at the Median preoptic 
nucleus (MnPO) and nucleus of the solitary tract (NTS). Bar graphs show relative Mu1 
mRNA gene expression in control [open bars] and sodium overload [filled bars] rats. Values 
are mean ± S.E.M., n=3-4/group. 
 
2.2 MOR G-protein activity measurements  
 To test the effect of high sodium intake treatment on MOR activity (efficacy and 
potency), we performed functional [35S]GTPγS binding assays. This type of assay can 
monitor the GDP→GTP exchange of the Gαi/o protein with the radioactive, non-hydrolyzable 
GTP analog, [35S]GTPγS, during agonist-mediated receptor activation. The MOR was 
stimulated with increasing concentrations of the highly MOR-selective pure agonist peptide 
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DAMGO. The assays were performed in control and experimental groups of rat brainstem 
membrane homogenate and in MnPO homogenates.   
 In the control group brainstem membrane homogenates, the agonist DAMGO 
increased the specific binding of [35S]GTPγS in MOR Gi/o protein in a concentration-
dependent manner. The increased specifically bound [35S]GTPγ S reached a 32% maximum 
over basal activity (100%), thus obtaining a total of 132% (± 2.6) maximum efficacy (Emax) 
for the MORs G-protein, with a 238.1 nM (pEC50: 6.62±0.2 M) potency (EC50) of the agonist 
DAMGO ( Fig. 3A). The 2% sodium intake significantly enhanced MOR agonist-mediated 
maximum G-protein efficacy (143.7%± 2.3; Fig. 3A), while the potency of DAMGO 
remained unaltered (pEC50: 6.81 ± 0.13 M; Fig 3A). 
 In the MnPO homogenates, DAMGO activated MORs G-protein over the basal 
activity more effectively than in the brainstem, since the activation resulted in 168.6% (± 3.6) 
MOR maximum efficacy, about 30% more than in the brainstem (Fig 3B). In the MnPO, the 
potency of DAMGO was slightly lower than in the brainstem, 271.4 nM (pEC50: 6.56±0.12 
M; Fig 3B). However, 2% sodium chloride consumption did not cause significant changes 
either in G-protein efficacy (163.5% ± 5.7; Fig. 3B) or in agonist potency (pEC50: 
6.41±0.2M; Fig 3B). 
 
Figure 3. MOR G-protein activity in DAMGO-stimulated [35S]GTPγS binding assays in rat 
brainstem membrane and MNPO homogenates during sodium overload. The figure represents 
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the specifically bound [35S]GTPγS in percentage in the presence of increasing concentrations 
(10-10-10-5 M) of DAMGO in control and after 2% NaCl treatment in rats in the indicated 
brain areas.* indicates the significant alteration in the Emax value after treatment (unpaired t-
test, two tailed P-value). Points and columns represent means ± S.E.M. for at least three 
experiments performed in triplicate. MOR basal activity was set as 100%. **: P<0.01. 
MnPO: median preoptic nucleus, MOR: μ-opioid receptor. 
 
2.3 MOR binding capacity measurements 
In the next step, we investigated the correlation of the enhanced G-protein activity of 
MOR and the higher levels of available MORs in brainstem after chronic sodium exposure. 
We performed saturation binding experiments, in which we saturated MORs with increasing 
concentrations of [3H]DAMGO. Thus we could calculate the maximal binding capacity 
(Bmax) of the MOR and the dissociation constant (Kd, binding affinity) of [3H]DAMGO after 
normal sodium or high sodium intake in brainstem membrane homogenates. The high sodium 
intake treatment did not change the maximal binding capacity of the MOR (96.2 fmol/mg ± 
7.9 vs. 86.3 fmol/mg ± 5.5; Fig 3) or the Kd value of the [3H]DAMGO (5.3 nM± 1 vs. 5 nM± 
0.8 nM; Fig 4). 
 
Figure 4. MOR maximal binding capacity during sodium overload in rat brainstem 
membrane homogenate in saturation binding experiments. The figure represents the 
specifically bound fixed [3H]DAMGO in cpm in increasing (0.7 nM – 50.3 nM) 
concentrations in control and following 2% NaCl treatment. MOR: μ-opioid receptor; Bmax: 
maximum binding capacity; cpm: counts per minute.  
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2.4 Plasma osmolality, electrolyte and body weight analysis 
No differences were observed in plasma osmolality and plasma electrolyte 
concentrations in control and experimental groups (Table 2). However, the 4 days- 2% NaCl 
ingestion reduced the weight gains in both Wistar and Sprague-Dawley rats in comparison 
with their respective control groups (Table 3). 
Table 2. Plasma osmolality and electrolyte concentrations after 4 days of sodium overload. 
 CON 2%NaCl 
OSM (mOsm/kg-H2O) 309 ± 1.97 314.14 ± 4.27 
Na+ (mEq/l) 140.12 ± 1.08 140.88 ± 1.35 
K+ (mEq/l) 8.03 ± 0.11 9.06 ± 0.31 
Cl- (mEq/l) 99.90 ± 2.32 99.76 ± 2.27 
 
Table 3. Body weights (initial, final and delta) in the control and experimental groups of 
Wistar and Sprague Dawley rats after 4 days drinking water or 2% NaCl solution, 
respectively (n=10-12). 
 Wistar Sprague-Dawley 
CON 2%NaCl CON 2%NaCl 
Initial body weight (g) 376.67 ± 11.15 373.71 ± 12.63 301.58± 4.11 304.92 ± 3.87
Final body weight (g) 431.33 ± 8.97 399.86 ± 12.46 342.83± 2.99 333.5 ± 3.59 
Gain in weight (g) 54.67 ± 4.22 26.14 ± 9.72* 41.25 ± 3.37 28.58 ± 1.77*
*: indicates the significant difference compared to CON (t test, P<0.05) 
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3 DISCUSSION 
Based on previous data demonstrating the importance of MOR signaling in body sodium 
homeostatic responses, the present study aimed to investigate whether increased salt intake in 
rats may induce changes in MOR mRNA expression, G-protein activity and MOR binding 
capacity, in brain regions previously involved in salt intake and blood pressure regulation. 
Although, after 4 days of obligatory hypertonic sodium chloride intake, there was no 
difference in the binding properties of the MOR system, there were clearly evident changes in 
the maximal efficacy of MORs G-protein, increasing the receptor activity for signaling within 
the brainstem. 
Our results also showed that, at least along the MnPO and at brainstem level, MOR binding 
capacity and mRNA receptor expression did not change and so these did not explain the β-
endorphin modulation after sodium loading conditions. If we hypothesize that more receptors 
are available on the surface membrane along the brainstem, then more G-proteins could 
couple to them, thus increasing their maximum efficacy. However, our saturation binding 
experiments exclude this hypothesis: the MORs were saturated to a nearly equal level in the 
control and experimental groups in this brain region, indicating no alteration in the number of 
available MORs on the cell surface. This was confirmed by our G-protein activity 
measurements, in which the control and experimental brain samples had similar radioactivity 
values of specifically bound [35S]GTPγS (data not shown). We can also rule out the 
possibility of improved binding capacities of MORs after the high salt intake, since neither 
the potency nor the dissociation constant was altered in the brainstem, parameters which 
describe the binding properties of DAMGO and [3H]DAMGO, respectively. The most likely 
explanation of our results is that the amount of Gi/o-protein available for coupling was 
increased after four days of hypertonic sodium intake, perhaps to activate this system that 
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counterbalanced the sodium-overload increase in sympathetic activity and blood pressure and 
provoked the well-known sodium overload-induced anorexia. 
Sodium ion has long been known to inhibit opioid agonist binding at near physiological 
concentrations (100-140 mM) in vitro(29,30), and, moreover, a distinct binding pocket on the 
MOR has recently been described for the ion(31). It has also been demonstrated that lower 
sodium concentrations increased basal G-protein coupling, which reduced the DAMGO-
mediated MOR G-protein maximum stimulation(32). The sodium ion can also promote the 
activation of the MOR by enhancing the movement of water molecules toward the allosteric 
site, as molecular dynamics simulations indicate(33). Although there were no differences in 
plasma sodium concentration between control and experimental groups when monitored after 
4 days of 2% NaCl ingestion, sodium concentrations may change during the 4-day study, 
contributing to the enhancement of G-protein activity. Thus, a “sodium effect” on MOR 
binding and signaling cannot be entirely excluded. 
Another interesting observation of this model was that, despite the plasma sodium 
concentration and osmolality remaining at the physiological level, reflecting the different 
types of efficient renal compensatory mechanisms, the animals’ body weight after 4 days of 
2% NaCl ingestion was significantly lower than that of the control group (Table 3). This may 
reflect a loss of body fluid stimulated by renal mechanisms trying to compensate the high 
plasma sodium concentration, and particularly the natriuresis-driven diuretic water loss 
mechanism. On the other hand, our preliminary food intake data (not shown) indicate that 
there is a comparatively reduced food intake in sodium overload animals, which may also 
explain their body weight loss. However, another mechanism triggered by dietary high salt 
intake during long term studies (100-200 days) has been recently described(34). In this case, 
high salt intake may reprioritize osmolality and energy metabolism for body fluid 
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conservation (mainly by urea production by liver and skeletal muscle), which provokes a 
reduction in body weight. This stage may be still not reached in our short-term study. 
The brainstem pathways leading to the perception of salt involve a circuitry in which the NTS 
and LPBN are the key sites that receive and integrate both homeostatic salt and satiety 
signals. The LPBN, for example, receives direct inputs from central osmo-sodium receptors 
located in the sensory circumventricular organs of the lamina terminalis, and indirect inputs 
from peripheral osmoreceptors through the vagus nerve(35). Many neurotransmitters/ 
neuromodulators regulate its responses (5-HT, angiotensin, GABA, noradrenaline) and opioid 
signaling has been shown to modulate salt appetite (20, 21 36). The LPBN contains neurons that 
express enkephalins and MORs(37), and pharmacological activation of MOR within this 
nucleus increases salt consumption(20,21). A second major pathway within the brainstem 
through which the brain detects body sodium status is via neurons that reside in the 
dorsocaudal subregion of the NTS that has fenestrated capillaries and expresses 11β-
hydroxysteroid dehydrogenase type 2(38). This nucleus contains the second order salt-
sensitive neurons that receive gustatory information coming from the first order sensory 
neurons within the lingual branch of the glossopharyngeal nerve, the superficial petrosal 
branch of the facial nerve and the laryngeal branch of the vagus nerve(39). In addition to 
receiving gustatory information about salt, it is important to take into account that a bi-
directional opioid–opioid signaling pathway exists between the rostral NTS and the central 
amygdala (CeA), which influences appetitive behaviors such as food intake via MORs(40). A 
similar opioid circuitry exists within the LPBN that projects to the CeA, which then activates 
the mesolimbic reward system involved in the motivation to consume salt and its rewarding 
palatability(5,17,41). 
In conclusion, our study has revealed that acute sodium overconsumption increases the 
maximal efficacy of MORs G-protein, increasing the receptor activity for signaling within the 
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brainstem. This probably reflects the influence of the endogenous brainstem u-opioid receptor 
system in regulating the maintenance of normal blood pressure levels and/or enhancing sodium taste 
aversion and sodium overload-induced anorexia in response to central and visceral homeostatic 
inputs. For further studies, it would be interesting to examine whether the enhanced MOR G-
protein activity further affects Gi/o-mediated signaling, such as adenylate cyclase activity. 
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